Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | $585.40M | $667.50M | $649.70M |
| Cost of revenue | $305.20M | $282.70M | $348.00M | $309.60M | $306.30M | $279.40M | $325.60M | $293.80M |
| Gross profit | $345.80M | $309.40M | $345.20M | $343.40M | $345.30M | $306.00M | $341.90M | $355.90M |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% |
| Research and development | $61.20M | $62.90M | $70.30M | $71.30M | $60.50M | $73.50M | $79.60M | $91.00M |
| Selling, general and administrative | $212.00M | $212.40M | $221.00M | $206.80M | $207.70M | $208.80M | $204.00M | $200.40M |
| Operating expenses | $273.20M | $275.30M | $291.30M | $278.10M | $268.20M | $282.30M | $283.60M | $291.40M |
| Operating income | $72.60M | $34.10M | $53.90M | $65.30M | $77.10M | $23.70M | $58.30M | $64.50M |
| Operating margin | 11.2% | 5.8% | 7.8% | 10.0% | 11.8% | 4.0% | 8.7% | 9.9% |
| EBITDA | $72.60M | $34.10M | $53.90M | $65.30M | $77.10M | $23.70M | $58.30M | $64.50M |
| Interest expense | −$12.10M | −$12.30M | −$12.10M | −$12.30M | −$12.60M | −$12.00M | −$12.20M | −$12.10M |
| Income before taxes | $542.10M | −$689.80M | $929.20M | −$431.10M | $414.00M | $83.40M | −$908.90M | $861.60M |
| Income taxes | $170.70M | −$162.70M | $209.20M | −$89.20M | $96.20M | $19.40M | −$193.10M | $208.40M |
| Net income | $371.40M | −$527.10M | $720.00M | −$341.90M | $317.80M | $64.00M | −$715.80M | $653.20M |
| Net margin | 57.1% | -89.0% | 103.9% | -52.4% | 48.8% | 10.9% | -107.2% | 100.5% |
| EPS, basic | $13.89 | −$19.55 | $26.70 | −$12.70 | $11.67 | $2.29 | −$25.57 | $23.37 |
| EPS, diluted | $13.85 | −$19.55 | $26.65 | −$12.70 | $11.67 | $2.29 | −$25.62 | $23.34 |
| Diluted shares | 26.81M | 26.96M | 27.02M | 26.92M | 27.23M | 27.96M | 27.94M | 27.99M |
Figures describe Bio-Rad Laboratories shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.